

# MARINOMED BIOTECH AG

ISIN: ATMARINOMED6 WKN: - Asset Class: **Stock**

## Company

2024/06/03 15:13:21



Price

**13.75**

EUR

Difference

**-1.79% (-0.25)**



## Contact Details

MARINOMED BIOTECH AG Tel: +43-1-2262-90300  
 -- Fax: +43-1-25077-4493  
 Hovengasse 25 Web: <http://www.marinomed.com>  
 2100 Korneuburg E-mail: -

## Company Profile

Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. It operates through the following segments: Immunology, Virology, and Other. The company was founded by Andreas Grassauer and Eva Prieschl-Grassauer in 2006 and is headquartered in Korneuburg, Austria.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	7,135,000		14,267,000		12,877,000	
<b>Common stock capital</b>		1,523,000		1,506,000		1,480,000
<b>Fixed assets</b>	7,476,000		8,019,000		8,459,000	
<b>Equity capital of a company</b>		-10,136,000		-4,157,000		191,000
<b>Cash and cash equivalents</b>	2,588,000		8,175,000		5,802,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		9,653,000		5,956,000		6,013,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		15,094,000		20,487,000		15,131,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		254,000		304,000		87,000
<b>Total assets</b>	14,611,000	14,611,000	22,286,000	22,286,000	21,337,000	21,337,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	52	49	47
<b>Equity ratio</b>	-69.37%	-18.65%	0.90%
<b>Debt-equity ratio</b>	-244.15%	-636.11%	11,047.86%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	-0.06%	-0.11%	-3.46%

# MARINOMED BIOTECH AG

ISIN: ATMARINOMED6 WKN: - Asset Class: **Stock**

## Income statement

	2023	2022	2021
<b>Turnover</b>	9,183,000	11,275,000	11,627,000
<b>Net income</b>	-6,794,000	-6,397,000	-5,891,000
<b>EBIT</b>	-4,317,800	-3,882,900	-4,185,100
<b>Operating income before taxes</b>	-6,790,000	-6,390,000	-5,694,000
<b>Cash Flow</b>	-4,528,000	-5,202,000	-4,866,000
<b>Net interest income</b>	-2,473,000	-2,508,000	-1,509,000
<b>Research and development expenses</b>	7,032,000	6,905,000	7,504,000
<b>Income taxes</b>	4,000	6,000	197,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	176,606	230,120	247,400

## Board of Directors

Simon Nebel	Chairman of Supervisory Board
Elisabeth Lackner	Member of Supervisory Board
Eva Hofstädter-Thalmann	Member of Supervisory Board
Brigitte Ederer	Member of Supervisory Board
Ulrich Kinzel	Member of Supervisory Board

## Members of Management Board

Andreas Grassauer	Chairman of Managing Board
Eva Prieschl-Grassauer	Member of Executive Committee
Pascal Schmidt	Member of Executive Committee